Marketed mixture
CJC-1295 + Ipamorelin
The most commonly marketed growth-hormone-axis pairing: a GHRH-type peptide combined with a ghrelin-receptor secretagogue.
Also seen as: CJC/Ipa, CJC-1295 with ipamorelin, Mod GRF + ipamorelin
A marketed blend name is not a standard formulation.
What the name usually refers to
Any honest record of this pairing must state whether the CJC component is DAC CJC-1295 or Modified GRF(1-29) / 'no DAC'. Amounts and ratios are formulation-specific and are not recorded here.
- CJC-1295 — read the evidence profile
Critical ambiguity: 'CJC-1295' is used both for the DAC version (with Drug Affinity Complex, long-acting) and for Modified GRF(1-29), often sold as 'CJC-1295 no DAC', which behaves very differently. A blend label that does not specify which one is describing an unknown product.
- Ipamorelin — read the evidence profile
Blends are mixtures sold under a nickname. The name is chosen by whoever is selling it, so two vials with the same name can contain different ingredients in different amounts. Any evidence level shown here describes the combined marketed mixture, which is almost always untested as a mixture.
Evidence for the mixture itself
- No blend-specific controlled human evidence identified in the curated record.
Both ingredients have human pharmacology data showing they can raise growth-hormone or IGF-1 markers. That is not the same as evidence for the combination, and it is not evidence of a clinical benefit such as muscle gain, fat loss or recovery. Combination effects cannot be inferred by adding separate endocrine responses together.
Why two vials with this name differ
Two products both labelled 'CJC-1295 + ipamorelin' can contain different molecules with different durations of action, so they are not the same product in any meaningful sense.
What is unknown about the formulation
- Whether the CJC component is the DAC version or Modified GRF(1-29).
- The proportions used, which are formulation-specific.
- How the two ingredients interact on the GH axis when given together in people.
- Whether any marker change translates into a clinical outcome.
Regulatory position
Neither ingredient is an approved medicine for the uses this pairing is marketed for, and the combination is not an approved product. Growth-hormone-axis compounds also sit under anti-doping prohibitions in tested sport.
Safety unknowns
- No controlled human safety dataset for the combination.
- Long-term consequences of sustained stimulation of the growth-hormone axis in healthy people are not established.
- Identity confusion between DAC and non-DAC material makes even the intended exposure uncertain.
References and sources
- To be curatedNo blend-specific controlled human study identified — source curation pending.